Two Phase III trials of PARP inhibitors in mCRPC

There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Final data from the failed, Phase III, AFFINITY trial of curstirsen + cabazitaxel + prednisone

In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …

Whatever happened to ARN-509?

Back in June 2013, Johnson & Johnson acquired Aragon Pharmaceuticals and the investigational agent ARN-509 — a potential “precursor” to abiraterone acetate (see below). … READ MORE …

OncoGenex completes enrollment of patients to Phase III trial of custirsen in mCRPC

Well, it’s taken a little over 2 years, but OncoGenex has completed enrollment of patients into the randomized, double-blind, Phase III SYNERGY trial, which is designed to assess whether the addition of custirsen (OGX-011) to docetaxel-based chemotherapy can extend the survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Side effect profile of MDV3100 appears highly promising in mCRPC

According to a number of media reports today, Medivation’s investigational drug MDV3100 appears to have a relatively good safety profile, although five patients who received MDV3100 in the completed Phase III trial did have seizures. … READ MORE …

Barvarian Nordic starts multi-center, Phase III trial of Prostvac

Barvarian Nordic has initiated the expected, randomized, multi-center Phase III trial of Prostvac® in men with asymptomatic and minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Two phase III trials planned for cabozantinib in mCRPC

Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC): … READ MORE …